OBJECTIVE—The aim of this study was to assess the accuracy of real-time myocardial contrast perfusion imaging (MCPI) during dobutamine stress in the diagnosis and localization of coronary artery disease (CAD) in patients with diabetes. Myocardial contrast echocardiography is a new technique that allows evaluation of myocardial perfusion. Its utility in diabetic patients has not been defined.

RESEARCH DESIGN AND METHODS—Dobutamine-atropine stress test was performed in conjunction with MCPI using Optison or Definity at rest and at peak stress in 128 patients with diabetes and suspected CAD who underwent coronary angiography within 1 month. CAD was defined as ≥50% stenosis in one or more coronary artery. MCPI was considered diagnostic of CAD in the presence of reversible perfusion abnormalities. The normalcy rate of MCPI was additionally determined in 18 asymptomatic nondiabetic patients with low probability.

RESULTS—CAD was detected in 101 (79%) patients by angiography. Reversible perfusion abnormalities were detected in 90 patients with and 13 patients without CAD. The overall sensitivity of MCPI was 89% (95% CI 83–95), specificity 52% (33–71), and accuracy 81% (75–88). Reversible abnormalities were detected in two or more vascular distributions in 44 of 56 patients with multivessel CAD and in 8 of 63 patients without (sensitivity 68%, specificity 87%, positive predictive value 84%, and accuracy 79%). Regional sensitivity was 75% (65–85) for left anterior descending CAD, 71% (60–83) for left circumflex, and 67% (55–78) for right CAD. MCPI was normal in 16 of the 18 patients with low clinical probability of CAD (normalcy rate 89%).

CONCLUSIONS—MCPI is a useful noninvasive technique for the diagnosis and localization of CAD in diabetic patients. The extent of perfusion abnormalities can identify patients with multivessel CAD with a moderate sensitivity and high specificity.

Coronary artery disease (CAD) is a leading cause of morbidity and mortality in patients with diabetes (15). Among patients with CAD, diabetes is associated with a worse prognosis (68). Angiographic studies have shown that patients with diabetes have more advanced CAD at the time of the diagnosis. Although coronary angiography remains the gold standard, the expense and risk associated with this procedure prohibit its routine use for diagnosis of CAD.

Various noninvasive stress imaging modalities are currently available for the evaluation of CAD in diabetic patients (1023). However, there are scarce data regarding the ability of noninvasive imaging techniques to identify multivessel CAD based on abnormalities in multivascular regions. This information is important since the extent of CAD determines the outcome, as well as potential benefit, of revascularization (24,25). Dobutamine stress echocardiography (DSE) has been reported as a safe method for evaluation of CAD in diabetic patients (23). Nevertheless, there are limited data regarding the diagnostic accuracy of this technique. Previous studies included in a small number of patients and have yielded contradictory results (1416,23).

Impairment of myocardial perfusion is an early event in the ischemic cascade (26). To date, studies of myocardial perfusion in diabetic patients were performed mainly with nuclear techniques (12,13). Myocardial contrast echocardiography is a newly introduced technique for the evaluation of myocardial perfusion in patients with suspected CAD (2735). Real-time imaging using low mechanical index pulse sequence schemes enhances the detection of microbubbles and reduces microbubble destruction. This permits the real-time identification of perfusion abnormalities during stress echocardiography without the need for ionizing radiation (29,32,33). The utility of real-time myocardial contrast perfusion imaging (MCPI) for the diagnosis of CAD in diabetic patients has not been studied. The aim of this study was to assess the accuracy of MCPI during DSE for the diagnosis and localization of CAD in patients with diabetes.

We studied 128 patients with diabetes referred for evaluation of CAD by dobutamine stress MCPI in our laboratory between February 2001 and August 2004. The patients underwent coronary angiography within 1 month, according to the discretion of the treating physician. Forty-one patients (32%) were screened because of multiple risk factors without cardiac symptoms. Clinical data and reasons for stress testing are presented in Table 1. The normalcy rate of MCPI was derived in 18 additional patients without diabetes who had low pretest probability of CAD (mean age 34 ± 5 years, 8 women). These subjects did not undergo coronary angiography. A low probability of CAD was considered if patients were <40 years of age, had no cardiac symptoms, had less than two risk factors for CAD, had normal baseline electrocardiogram and no history of stroke, or had peripheral vascular disease, nephropathy, neuropathy, or myocardial infarction. Patients gave informed consent to undergo the stress test. The study was approved by the institutional review board of the University of Nebraska Medical Center.

Diabetes was defined as a fasting glucose level ≥140 mg/dl or the need for insulin or oral hypoglycemic agents. Hypercholesterolemia was defined as a total cholesterol ≥200 mg/dl or treatment with lipid-lowering medications. Proliferative retinopathy was determined by stereo fundus examination or a history of laser therapy for proliferative disease. Overt nephropathy was defined as an albumin excretion rate >200 μg/min on at least two of three timed urine samples and/or a serum creatinine level >2 mg/dl, renal failure, or renal transplant. Peripheral neuropathy was considered present if there was decreased or absent deep tendon reflexes or signs of sensory loss. Peripheral vascular disease was defined by a history of amputation or claudication or an ankle-brachial index <0.9 at rest. Hypertension was defined as blood pressure 140/90 mmHg or use of antihypertensive medication (36).

Dobutamine stress test

Patients were instructed to discontinue β-blockers 24 h before the stress test. Dobutamine was infused at a starting dose of 5 μg · kg−1 · min−1 for 3–5 min, followed by 10 μg · kg−1 · min−1 for 3–5 min. The dobutamine dose was subsequently increased by 10 μg · kg−1 · min−1 every 3 min up to a maximum dose of 50 μg · kg−1 · min−1. Atropine (up to 2 mg) was intravenously administered to achieve 85% of maximal predicted heart rate (220 − age). Reasons for test termination were achievement of target heart rate, maximal dose of dobutamine and atropine, hypertension (blood pressure >240/120 mmHg), symptomatic decrease in systolic blood pressure, symptomatic or sustained nonsinus tachycardia, and ST segment depression >2 mm in electrocardiogram leads without resting ST depression, severe angina, and any intolerable adverse effect considered to be the result of dobutamine or atropine. Metoprolol (1–10 mg) was used intravenously to reverse the side effects of dobutamine if these did not revert quickly after termination of the stress test.

Echocardiographic imaging

The contrast agents used for the study were perfluorocarbon-containing albumin-coated microbubbles (Optison; Mallinckrodt, St. Louis, MO; GE-Amersham, Princeton, NJ) in 87 patients and lipid-encapsulated perfluoropropane-filled microbubbles (Definity; Bristol-Myers Squibb Medical Imaging, North Billerica, MA) in 41 patients. Imaging was performed using commercially available ultrasound scanners (Philips Sonos 5500, Philips HDI 5000, or Siemens Acuson Sequoia C512) equipped with low–mechanical index real-time pulse sequence schemes. Imaging was performed by the use of pulse inversion Doppler (Philips ATL), Contrast Pulse Sequencing (Siemens Acuson Sequoia), or Power Modulation (Philips Agilent). The equipment was adjusted to achieve maximal nonlinear signal from contrast. Mechanical indexes were set to ≤0.3 and frame rate to ≥25 Hz. Time gain compensation and two-dimensional gain settings were adjusted to suppress signals from the myocardium before contrast injection. Images from apical views (four-chamber, two-chamber, and long-axis views) were obtained and digitized at rest and at maximal stress after the patient achieved ≥85% predicted maximum heart rate or a test end point.

After optimization of the settings, a 0.2- to 0.3-ml calibration dose of Optison or 0.1- to 0.15-ml dose of Definity followed by saline flush was given. Setting corrections were made to optimize gain and minimize any tissue nonlinear signals. Imaging began with a similar contrast dose in the apical four-chamber view. A minimum of 15 s of image acquisition was performed following peak myocardial opacification until disappearance of contrast from the myocardium. Imaging was acquired from the apical two-chamber and apical long-axis views using the same method.

Myocardial perfusion was interpreted using the 16-segment model (37) by an independent investigator who was blinded to clinical data. Studies were interpreted as either normal or abnormal in each of the three coronary arterial territories. A reversible perfusion abnormality was defined as a perfusion defect during stress imaging that was not observed at resting imaging. This was considered diagnostic of CAD. A reversible defect was considered present when two contiguous segments failed to exhibited contrast enhancement during the washout of contrast following the bolus injection, as compared with other segments at the same depth in the same view. Contrast enhancement was additionally compared with the same segment at rest using a side-by-side image analysis. Attenuation from contrast or lung interference was considered present if any segment could not be visualized and was not distinguishable from surrounding tissue. The interobserver agreement on the presence of reversible perfusion defects on MCPI in our laboratory is 92%. The intraobserver agreement is 92% (27).

The anterior septum, mid-posterior septum, anterior wall, and adjacent apical segments were assigned to the left anterior descending coronary artery (LAD). The lateral segments were assigned to the left circumflex coronary artery (LCx). The inferior and basal septal segments were assigned to the right coronary artery (RCA). The posterior wall was considered an overlap region and was assigned to either the LCx or RCA distribution. The apical inferior/posterior segments were also considered overlap regions and were assigned to the vascular territory with contiguous abnormalities. MCPI was considered diagnostic for CAD in the presence of reversible perfusion abnormalities. The feasibility for interpretation of stress MCPI in our laboratory is 96% for LAD distribution, 95% for RCA distribution, and 94% for LCx distribution (38).

Quantitative angiography

Coronary angiography was performed within 1 month (9 ± 7 days [means ± SD]) after the DSE using the Judkins’ technique. Quantitative measurements of coronary artery stenosis were made by an experienced interventional cardiologist blinded to DSE results using a hand-held electronic caliper (Tesa, Renens, Switzerland) (39). Measurements were expressed as the percentage of diameter narrowing using the diameter of the nearest normal-appearing region as a reference. CAD was defined as ≥50% luminal diameter stenosis in one or more major epicardial vessel. Twenty patients had previous coronary artery bypass surgery. In these patients, CAD was defined as ≥50% luminal diameter stenosis of a nongrafted major coronary artery or ≥50% luminal diameter stenosis of the vein or arterial bypass graft.

Statistical analysis

Continuous variables were compared using Student’s t test and are presented as means ± SD. Sensitivity, specificity, and accuracy were calculated using standard definitions and are presented with 95% CIs. Comparison of proportions was made by χ2 test. A P value <0.05 was considered significant.

Coronary angiography

CAD (≥50% stenosis) was detected in 101 (79%) patients. Among these patients, 36 had single-vessel, 41 had two-vessel, and 24 had three-vessel CAD. The remaining 27 patients had no significant CAD. Coronary artery stenoses involved the LAD in 68 (53%), RCA in 63 (49%), and LCx in 59 (46%) patients.

Dobutamine stress test

The stress test was performed in all patients without serious complications. No death or myocardial infarction occurred during or immediately after the stress test. Dobutamine-atropine induced significant changes in heart rate (76 ± 17 vs. 140 ± 15 bpm), whereas systolic blood pressure did not change (148 ± 30 vs. 148 ± 34 mmHg) from rest to peak stress, respectively. Atropine was administered in 88 (69%) patients with a mean dose of 0.6 ± 0.5 mg. Chest pain occurred in 47 (37%) patients, and ST segment depression (>0.1 mV horizontal or downsloping) occurred in 15 (12%) patients. The target heart rate was achieved in 116 (91%) patients. One patient had nonsustained ventricular tachycardia, and two patients had a brief episode of supraventricular tachycardia. MPCI was feasible in all patients. Myocardial perfusion abnormalities were detected at baseline imaging in 29 (23%) patients. Among these patients, 26 had previous myocardial infarction. Reversible perfusion abnormalities occurred in 103 (80%) patients.

Diagnostic accuracy of MCPI

Reversible myocardial perfusion abnormalities were detected in 90 of 101 patients with and 13 of 27 patients without significant CAD. Sensitivity was 89% (95% CI 83–95), specificity 52% (33–71), and accuracy 81% (75–88).

Reversible perfusion abnormalities were detected in two or more vascular distributions in 44 of 56 patients with multivessel CAD and in eight of 63 patients without multivessel CAD (sensitivity for the detection of multivessel disease 68% [56–79], specificity 87% [79–96], positive predictive value 84% [74–94], negative predictive value 71% [59–84], and accuracy 79% [70–85]). Figure 1 presents echocardiographic images of a 33-year-old man with no cardiac symptoms who had type 1 diabetes, hypertension, hypercholesterolemia, retinopathy, and nephropathy. The patient developed perfusion defects in the anterior septum during dobutamine stress. Coronary angiography revealed a proximal subtotal occlusion of LAD. Twenty six of the 29 patients with resting perfusion abnormalities had previous myocardial infarction. In the 29 patients who had a resting perfusion abnormality, significant stenosis of the related coronary artery was detected in 23 patients, resulting in a regional specificity of 79%.

Regional accuracy.

Table 2 presents the accuracy of MCPI for the regional diagnosis of CAD. No significant differences were detected regarding the sensitivity, specificity, or accuracy of MCPI in the three arterial regions.

Normalcy rate.

Perfusion abnormalities were detected in 2 of the 18 patients with low pretest probability of CAD, yielding a normalcy rate of 89% (95% CI 74–99).

Identification of diabetic patients at high risk for cardiac events is an important step in the determination of a management strategy. The extent of CAD is a known predictor of cardiac mortality and identifies patients who receive the greatest benefit from revascularization procedures (24,25). There are limited data regarding the accuracy of stress imaging techniques in the diagnosis of CAD in diabetic patients. Furthermore, data regarding the estimation of extent of CAD in diabetic patients are scarce. Although patients with multivessel CAD often demonstrate abnormalities during stress imaging, these are often detected in a single vascular region with underestimation of the extent of CAD. In general, the sensitivity of DSE for identifying multivessel CAD based on inducible wall motion abnormalities in multivascular regions has ranged from 8 to 71% (40,41).

In this study we demonstrated that MCPI is a safe method for diagnosis of CAD in 128 patients with diabetes. Reversible perfusion abnormalities during dobutamine stress had a high sensitivity (89%) and accuracy (81%) with a modest specificity for the diagnosis of CAD. The majority of patients (68%) with multivessel CAD were identified based on the presence of reversible perfusion abnormalities in a multivessel distribution. This perfusion pattern provided a specificity of 87% for multivessel CAD. The accuracy was maintained in the three major coronary distributions. These findings suggest that MCPI is a promising technique for evaluating the extent of CAD and identifying diabetic patients who have the largest functional area at risk.

To date, clinical studies of myocardial perfusion in diabetic patients were mainly performed with nuclear techniques. The current study suggests that MCPI potentially could be an alternative echocardiographic method for the evaluation of myocardial perfusion in diabetic patients. In contrast to the nuclear techniques, MCPI does not require ionizing irradiation or a nuclear scanner and provides immediate assessment of perfusion. Stress and rest images are acquired in the same setting with MCPI, whereas they are acquired in two different settings with nuclear imaging.

Previous studies of DSE in diabetes

Despite the growing evidence of the clinical utility of DSE, studies of the diagnostic accuracy in diabetic patients are limited by including only a small number of patients. Most of the studies reported a low to modest sensitivity in single-vessel CAD. Bacci et al. (14) evaluated the accuracy of DSE in 35 asymptomatic high-risk type 2 diabetic patients. Significant CAD was defined as 70% lumen reduction and was detected in 19 patients. The sensitivity of DSE was 21%, specificity 94%, and accuracy was 54%. Penfornis et al. (15) compared the efficacy of exercise thallium-201 tomography and DSE in detecting CAD in 26 asymptomatic diabetic patients with three or more risk factors. Predictive positive value was 69% for DSE and 75% for thallium-201 imaging.

Elhendy et al. (23) reported that in 55 diabetic patients with known or suspected CAD, the sensitivity, specificity, and accuracy of DSE were 81, 85, and 82%, respectively. Sensitivity was 60% in patients with single-vessel CAD. Among the 31 patients with multivessel CAD, the sensitivity of DSE based on inducible wall motion abnormalities in multivascular regions was 51%. Hennessy et al. (16) studied 52 diabetic patients with DSE and coronary angiography. The sensitivity, specificity, positive predictive value, and negative predictive value of DSE for detection of CAD were 82, 54, 84, and 50%, respectively.

Studies with stress radionuclide imaging in diabetes

Kumar et al. (12) studied 43 diabetic patients with suspected CAD by exercise thallium imaging. CAD was detected in 24 patients. Sensitivity of thallium imaging was 87.5% and specificity 84%. Kang et al. (13) studied 138 diabetic patients with stress dual-isotope myocardial perfusion imaging and coronary angiography within 6 months. The sensitivity and specificity of perfusion imaging for detecting CAD with the criterion of ≥50% diameter stenosis were 86 and 56%, respectively. The normalcy rate for low-likelihood patients was 89% (58 of 65 patients). Paillole et al. (17) determined the accuracy of intravenous dipyridamole myocardial thallium scintigraphy in 59 middle-aged diabetic patients with suspected CAD. Twenty patients had >70% coronary artery stenosis. The sensitivity and specificity for thallium scintigraphy were 80 and 87%, respectively.

Diagnostic accuracy in the three coronary arterial distributions

Previous studies have demonstrated a modest sensitivity for DSE in diagnosing significant CAD in an individual coronary artery, as well as in patients with single-vessel CAD (39,40). In our study, myocardial contrast echocardiography had a good sensitivity and accuracy for the diagnosis of LAD, RCA, and LCx CAD. The location of perfusion abnormality was accurate in localizing significant disease in the corresponding coronary artery, with a specificity of 73% for LAD and 83% for both RCA and LCx disease. This information is potentially useful for the physician when deciding which coronary arterial segments may require revascularization, particularly in those with complex angiographic abnormalities.

Limitations of the study

Coronary angiography was performed according to the discretion of the treating physician and not per study protocol. Therefore, referral bias may have influenced the results of the study. This may explain the higher prevalence of CAD and the low specificity of MCPI due to possible verification bias in patients with reversible perfusion abnormalities. Another explanation of the low specificity of MCPI could be the presence of artifactual defects in the apical and basal segments due to near field destruction and lung interference. It is possible that impairment of vasodilator reserve may occur in the absence of a major coronary arterial narrowing. This has been particularly observed in diabetes due to impairment of endothelial function (42,43). Although the normalcy rate in this study was 89% in patients with low pretest probability, CAD certainly cannot be excluded in these patients without coronary angiography.

The study consisted of a heterogeneous population with and without symptoms, with possible bias related to referral for stress testing and subsequent angiography. Finally, MCPI requires a high level of experience and is still largely an experimental tool in most stress laboratories. Further studies from other centers are needed to confirm our data before recommending this technique as a standard clinical tool.

Figure 1—

Echocardiographic images from the apical long-axis view at rest (A) and at peak dobutamine stress (B) in a 33-year-old man with no cardiac symptoms who had type 1 diabetes, hypertension, hypercholesterolemia, nephropathy, and retinopathy. A reversible subendocardial perfusion abnormality in the entire anterior septum during stress is indicated by arrows (B). C: Subsequent coronary angiography (Angio; right anterior oblique view) demonstrated a proximal subtotal occlusion of the LAD (indicated by arrow).

Figure 1—

Echocardiographic images from the apical long-axis view at rest (A) and at peak dobutamine stress (B) in a 33-year-old man with no cardiac symptoms who had type 1 diabetes, hypertension, hypercholesterolemia, nephropathy, and retinopathy. A reversible subendocardial perfusion abnormality in the entire anterior septum during stress is indicated by arrows (B). C: Subsequent coronary angiography (Angio; right anterior oblique view) demonstrated a proximal subtotal occlusion of the LAD (indicated by arrow).

Close modal
Table 1—

Clinical data of the study patients

Clinical parameters
Reasons for referral  
    Evaluation of chest pain 57 (45) 
    Multiple risk factors 41 (32) 
    Perioperative risk assessment 30 (23) 
Type 1 diabetes 26 (20) 
Previous myocardial infarction 28 (22) 
Hypertension 98 (77) 
Hypercholesterolemia 83 (65) 
Cigarette smoking 29 (23) 
β-Blockers 68 (53) 
Calcium channel blockers 35 (27) 
Diabetes management  
    Insulin 32 (25) 
    Oral hypoglycemic agents 61 (48) 
    Both 21 (16) 
    Diet only 14 (11) 
Peripheral vascular disease 11 (9) 
Peripheral neuropathy 12 (9) 
Overt nephropathy 44 (35) 
Previous stroke 8 (6) 
Proliferative retinopathy 11 (9) 
Ejection fraction (%) 55 ± 12 
Clinical parameters
Reasons for referral  
    Evaluation of chest pain 57 (45) 
    Multiple risk factors 41 (32) 
    Perioperative risk assessment 30 (23) 
Type 1 diabetes 26 (20) 
Previous myocardial infarction 28 (22) 
Hypertension 98 (77) 
Hypercholesterolemia 83 (65) 
Cigarette smoking 29 (23) 
β-Blockers 68 (53) 
Calcium channel blockers 35 (27) 
Diabetes management  
    Insulin 32 (25) 
    Oral hypoglycemic agents 61 (48) 
    Both 21 (16) 
    Diet only 14 (11) 
Peripheral vascular disease 11 (9) 
Peripheral neuropathy 12 (9) 
Overt nephropathy 44 (35) 
Previous stroke 8 (6) 
Proliferative retinopathy 11 (9) 
Ejection fraction (%) 55 ± 12 

Data are n (%) or means ± SD.

Table 2—

Regional accuracy of myocardial contrast echocardiography for the diagnosis of significant disease in the three major coronary arteries

Diagnostic parameterLADLCxRCA
Sensitivity 75 (65–85) 71 (60–83) 67 (55–78) 
Specificity 73 (62–85) 83 (74–92) 83 (74–92) 
Accuracy 76 (70–82) 77 (70–85) 75 (68–83) 
Diagnostic parameterLADLCxRCA
Sensitivity 75 (65–85) 71 (60–83) 67 (55–78) 
Specificity 73 (62–85) 83 (74–92) 83 (74–92) 
Accuracy 76 (70–82) 77 (70–85) 75 (68–83) 

Data are % (95% CI).

1.
Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR: Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Circulation
100
:
1134
–1146,
1999
2.
Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, Patterson CC: Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes.
Diabetologia
46
:
760
–765,
2003
3.
Vaccaro O, Eberly LE, Neaton JD, Yang L, Riccardi G, Stamler J: Multiple Risk Factor Intervention Trial Research Group: impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial.
Arch Intern Med
164
:
1438
–1443,
2004
4.
Haffner SM, Lehto S, Rename T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
N Engl J Med
339
:
229
–234,
1998
5.
Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, Nathan DM, Manson JE: The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up.
Arch Intern Med
161
:
1717
–1723,
2001
6.
Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, Tuomilehto J: Impact of diabetes on mortality after the first myocardial infarction.
Diabetes Care
21
:
69
–75,
1998
7.
Norhammar A, Malmberg K, Diderholm E, Lagerqvist B, Lindahl B, Ryden L, Wallentin L: Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization.
J Am Coll Cardiol
43
:
585
–591,
2004
8.
Cole JH, Miller JI 3rd, Sperling LS, Weintraub WS: Long-term follow-up of coronary artery disease presenting in young adults.
J Am Coll Cardiol
41
:
521
–528,
3003
9.
Ammann P, Brunner-La Rocca H, Fehr T, Munzer T, Sagmeister M, Angehrn W, Rickli H: Coronary anatomy and left ventricular ejection fraction in patients with type 2 diabetes admitted for elective coronary angiography.
Catheter Cardiovasc Interv
62
:
432
–438,
2004
10.
American Diabetes Association: Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10–11 February 1998, Miami, Florida (Review).
Diabetes Care
21
:
1551
–1559,
1998
11.
Inzucchi SE: Noninvasive assessment of the diabetic patient for coronary artery disease.
Diabetes Care
24
:
1519
–1521,
2001
12.
Kumar R, Patel CD, Marwah A, Gupta R, Sharma S, Malhotra A: Detection of coronary artery disease by stress thallium scintigraphy in diabetic patients.
Nucl Med Commun
22
:
287
–289,
2001
13.
Kang X, Berman DS, Lewin H, Miranda R, Erel J, Friedman JD, Amanullah AM: Comparative ability of myocardial perfusion single-photon emission computed tomography to detect coronary artery disease in patients with and without diabetes mellitus.
Am Heart J
137
:
949
–957,
1999
14.
Bacci S, Russo A, Rauseo A, Fanelli R, Trischitta V: The role of dobutamine stress echocardiography in detecting severe coronary artery disease in asymptomatic at high risk type 2 diabetic patients (Letter).
Diabetes Care
25
:
1659
,
2002
15.
Penfornis A, Zimmermann C, Boumal D, Sabbah A, Meneveau N, Gaultier-Bourgeois S, Bassand JP, Bernard Y: Use of dobutamine stress echocardiography in detecting silent myocardial ischaemia in asymptomatic diabetic patients: a comparison with thallium scintigraphy and exercise testing.
Diabet Med
18
:
900
–905,
2001
16.
Hennessy TG, Codd MB, Kane G, McCarthy C, McCann HA, Sugrue DD: Evaluation of patients with diabetes mellitus for coronary artery disease using dobutamine stress echocardiography.
Coron Artery Dis
8
:
171
–174,
1997
17.
Paillole C, Ruiz J, Juliard JM, Leblanc H, Gourgon R, Passa P: Detection of coronary artery disease in diabetic patients.
Diabetologia
38
:
726
–731,
1995
18.
Elhendy A, Arruda AM, Mahoney DW, Pellikka PA: Prognostic stratification of diabetic patients by exercise echocardiography.
J Am Coll Cardiol
37
:
1551
–1557,
2001
19.
Bigi R, Decider A, Cortigiani L, Bax JJ, Celeron L, Florentine C: Stress echocardiography for risk stratification of diabetic patients with known or suspected coronary artery disease.
Diabetes Care
24
:
1596
–1601,
2001
20.
Sozzi FB, Elhendy A, Roelandt JR, van Domburg RT, Schinkel AF, Vourvouri EC, Bax JJ, De Sutter J, Brochette A, Poldermans D: Prognostic value of dobutamine stress echocardiography in patients with diabetes.
Diabetes Care
26
:
1074
–1078,
2003
21.
Vanzetto G, Halimi S, Hammoud T, Fagret D, Benhamou P, Cordonnier D, Denis B, Machecourt J: Prediction of cardiovascular events in clinically selected high risk NIDDM patients: prognostic value of exercise stress test and thallium-201 single-photon emission computed tomography.
Diabetes Care
22
:
19
–26,
1999
22.
Schinkel AF, Elhendy A, van Domburg RT, Bax JJ, Vourvouri EC, Sozzi FB, Valkema R, Roelandt JR, Poldermans D: Prognostic value of dobutamine-atropine stress myocardial perfusion imaging in patients with diabetes.
Diabetes Care
25
:
1637
–1643,
2003
23.
Elhendy A, van Domburg RT, Poldermans D, Bax JJ, Nierop PR, Geleijnse ML, Roelandt JR: Safety and feasibility of dobutamine-atropine stress echocardiography for the diagnosis of coronary artery disease in diabetic patients unable to perform an exercise stress test.
Diabetes Care
21
:
1797
–1802,
1998
24.
Mancini GB, Bourassa MG, Williamson PR, Leclerc G, DeBoe SF, Pitt B, Lesperance J: Prognostic importance of quantitative analysis of coronary cineangiograms.
Am J Cardiol
69
:
1022
–1027,
1992
25.
Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC, Herrmann HC, Hillis LD, Hutter AM Jr, Lytle BW, Marlow RA, Nugent WC, Orszulak TA, American College of Cardiology, American Heart Association: ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery).
Circulation
110
:
340
–437,
2004
26.
Nesto RW, Kowalchuk GJ: The ischemic cascade: temporal sequence of hemodynamic, electrocardiographic and symptomatic expressions of ischemia.
Am J Cardiol
59
:
23C
–30C,
1987
27.
Elhendy A, O’leary EL, Xie F, McGrain AC, Anderson JR, Porter TR: Comparative accuracy of real-time myocardial contrast perfusion imaging and wall motion analysis during dobutamine stress echocardiography for the diagnosis of coronary artery disease.
J Am Coll Cardiol
44
:
2185
–2191,
2004
28.
Kaul S, Senior R, Dittrich H, Raval U, Khattar R, Lahiri A: Detection of coronary artery disease using myocardial contrast echocardiography: comparison with 99mTc-sestamibi single photon emission computed tomography.
Circulation
96
:
785
–792,
1997
29.
Wei K: Approaches to the detection of coronary artery disease using myocardial contrast echocardiography.
Am J Cardiol
90
:
48J
–58J,
2002
30.
Leistad E, Ohmori K, Peterson TA, Christensen G, DeMaria AN: Quantitative assessment of myocardial perfusion during graded coronary artery stenoses by intravenous myocardial contrast echocardiography.
J Am Coll Cardiol
37
:
624
–631,
2001
31.
Bin JP, Le DE, Jayaweera AR, Coggins MP, Wei K, Kaul S: Direct effects of dobutamine on the coronary microcirculation: comparison with adenosine using myocardial contrast echocardiography.
J Am Soc Echocardiogr
16
:
871
–879,
2003
32.
Porter TR, Xie F: Clinical experience in the detection of coronary artery disease with myocardial contrast echocardiography.
Echocardiography
19
:
399
–407,
2002
33.
Gunda M, Mulvagh SL: Recent advances in myocardial contrast echocardiography.
Curr Opin Cardiol
16
:
231
–239,
2001
34.
Laskar R, Grayburn PA: Assessment of myocardial perfusion with contrast echocardiography at rest and with stress: an emerging technology.
Prog Cardiovasc Dis
43
:
245
–258,
2000
35.
Mulvagh SL: Myocardial perfusion by contrast echocardiography: diagnosis of coronary artery disease using contrast-enhanced stress echocardiography and assessment of coronary anatomy and flow reserve.
Coron Artery Dis
11
:
243
–251,
2000
36.
Zgibor JC, Songer TJ, Kelsey SF, Drash AL, Orchard TJ: Influence of health care providers on the development of diabetes complications: long-term follow-up from the Pittsburgh Epidemiology of Diabetes Complications Study.
Diabetes Care
25
:
1584
–1590,
2002
37.
Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, Douglas PS, Faxon DP, Gillam LD, Kimball TR, Kussmaul WG, Pearlman AS, Philbrick JT, Rakowski H, Thys DM, Antman EM, Smith SC Jr, Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Faxon DP, Hunt SA, Fuster V, Jacobs AK, Gibbons RJ, Russell RO: ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography).
J Am Soc Echocardiogr
16
:
1091
–110,
2003
38.
Tsutsui JM, MD, Elhendy A, Xie F, O’Leary EL, MD, FACC, McGrain AC, Porter TR: Safety of dobutamine stress real-time myocardial contrast echocardiography.
J Am Coll Cardiol
45
:
1235
–1242,
2005
39.
Uehata A, Matsuguchi T, Bittl JA, Orav J, Meredith IT, Anderson TJ, Selwyn AP, Ganz P, Yeung A: Accuracy of electronic digital calipers compared with quantitative angiography in measuring coronary arterial diameter.
Circulation
88
:
1724
–1729,
1993
40.
Geleijnse ML, Fioretti PM, Roelandt JR: Methodology, feasibility, safety and diagnostic accuracy of dobutamine stress echocardiography (Review).
J Am Coll Cardiol
30
:
595
–606,
1997
41.
Elhendy A, van Domburg RT, Bax JJ, Poldermans D, Sozzi FB, Roelandt JR: Accuracy of dobutamine technetium 99m sestamibi SPECT imaging for the diagnosis of single-vessel coronary artery disease: comparison with echocardiography.
Am Heart J
139
:
224
–230,
2000
42.
Pitkanen OP, Nuutila P, Raitakari OT, Ronnemaa T, Koskinen PJ, Iida H, Lehtimaki TJ, Laine HK, Takala T, Viikari JS, Knuuti J: Coronary flow reserve is reduced in young men with IDDM.
Diabetes
47
:
248
–254,
1998
43.
Nahser PJ Jr, Brown RE, Oskarsson H, Winniford MD, Rossen JD: Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus.
Circulation
91
:
635
–640,
1995

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.